You do not currently have access to this content.
AbstractKRAS G12D is the most prevalent KRAS mutation in human cancers, present in 37%, 12.5%, and 4.9% of pancreatic, colorectal and lung cancers, respectively. Currently, there are no FDA-approved ...
Mol Cancer Ther (2025) 24 (10_Supplement): A068.
AbstractBackground:. Elisrasib is a next-generation KRAS G12C inhibitor (G12Ci) designed to improve target engagement (TE) efficiency and overcome growth factor-induced nucleotide exchange. This ...
Cancer Res (2025) 85 (8_Supplement_2): ND11.
AbstractAge at diagnosis among patients with cancer is a predictor of pathogenic germline variant prevalence, yet age thresholds often misclassify genetic risk. We performed germline sequencing of ...
Sarcopenia is strongly linked to poor survival outcomes and increased treatment-related toxicity in solid tumors. Both pre- and post-treatment muscle loss negatively impact prognosis, emphasizing the ...
Abstract. The KRASG12V variant mutation is the second most prevalent oncogenic alteration in KRAS-driven cancers that leads to aberrant activation of the mitogen-activated protein kinase (MAPK) ...
AbstractIntroduction:. Microsatellite instability (MSI) and tumor mutational burden (TMB) are key biomarkers guiding treatment decisions in oncology. While immunohistochemistry (IHC) remains the ...
Cancer Discov (2026) 16 (11): OF1.
1Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. *Corresponding Author: Jennifer L. Anderson, Department of Head and Neck Surgery, The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results